Chondroprotective effects of Salubrinal in a mouse model of osteoarthritis by Hamamura, K. et al.
VOL. 4, No. 5, MAY 2015 84
 GENERAL ORTHOPAEDICS
Chondroprotective effects of Salubrinal 
in a mouse model of osteoarthritis
K. Hamamura,
A. Nishimura,
T. Iino,
S. Takigawa,
A. Sudo,
H. Yokota
From Indiana 
University, Purdue 
University, Indianapolis, 
United States
 K. Hamamura, PhD, DDS, 
Dental Surgeon
 S. Takigawa, MD, Orthopaedic 
Surgeon
 H. Yokota, PhD, Professor, 
Department of Biomedical 
Engineering
Indiana University, Purdue 
University, Indianapolis, 723 
West Michigan Street, 
Indianapolis, Indiana 46202, 
USA.
 A. Nishimura, MD, PhD, 
Orthopaedic Surgeon
 T. Iino, Research Technician
 A. Sudo, MD, PhD, 
Orthopaedic Surgeon, Professor, 
Department of Orthopaedic 
Surgery
Mie University Graduate School 
of Medicine, Mie 514, Japan.
Correspondence should be sent 
to Dr K. Hamamura; email: 
hamak@dpc.agu.ac.jp
doi: 10.1302/2046-3758.45. 
2000378 $2.00
Bone Joint Res 2015;4:84–92. 
Received 23 November 2014; 
Accepted after revision 22 April 
2015
Objectives
Salubrinal is a synthetic agent that elevates phosphorylation of eukaryotic translation 
initiation factor 2 alpha (eIF2α) and alleviates stress to the endoplasmic reticulum. 
Previously, we reported that in chondrocytes, Salubrinal attenuates expression and 
activity of matrix metalloproteinase 13 (MMP13) through downregulating nuclear factor 
kappa B (NFB) signalling. We herein examine whether Salubrinal prevents the degradation 
of articular cartilage in a mouse model of osteoarthritis (OA).
Methods
OA was surgically induced in the left knee of female mice. Animal groups included age-
matched sham control, OA placebo, and OA treated with Salubrinal or Guanabenz. Three 
weeks after the induction of OA, immunoblotting was performed for NFB p65 and p-NFB 
p65. At three and six weeks, the femora and tibiae were isolated and the sagittal sections 
were stained with Safranin O.
Results
Salubrinal suppressed the progression of OA by downregulating p-NFB p65 and MMP13. 
Although Guanabenz elevates the phosphorylation level of eIF2α, it did not suppress the 
progression of OA.
Conclusions
Administration of Salubrinal has chondroprotective effects in arthritic joints. Salubrinal can 
be considered as a potential therapeutic agent for alleviating symptoms of OA.
Cite this article: Bone Joint Res 2015;4:84–92
Article focus
 The goal was to examine whether daily
administration of Salubrinal to a mouse
model of osteoarthritis (OA) alleviates the
degradation of articular cartilage in the
femur and tibia.
Key messages
 Salubrinal suppressed the progression
of OA by downregulating the phos-
phorylation of nuclear factor kappa B
p65 and the activity of matrix metallo-
proteinase 13.
 Although both Salubrinal and Guana-
benz suppress stress to the endoplasmic
reticulum, daily administration of
Guanabenz did not prevent the
progression of OA.
Strength and limitations
 Strengths: This is a pre-clinical study that
indicates novel treatment of patients with
OA. Salubrinal is a synthetic agent that
provides beneficial effects, not only by
delaying the progression of OA, but also
by preventing bone loss in a separate
mouse model of osteoporosis.
 Limitation: The observed effects on OA
should be further examined using both
female and male mice at different time
points and dosages of Salubrinal.
Introduction
Osteoarthritis (OA) is the most common form
of arthritis, resulting from multiple factors
including ageing, traumatic injuries and
abnormal gait biomechanics, as well as
Freely available online
Keywords: Salubrinal, Osteoarthritis, MMP13, NFB, Cartilage
85 K. HAMAMURA, A. NISHIMURA, T. IINO, S. TAKIGAWA, A. SUDO, H. YOKOTA
BONE & JOINT RESEARCH
genetic and metabolic elements linked to obesity and
inflammation.1-4 Approximately 630 million people are
affected worldwide, but injured cartilage does not heal
spontaneously. In many cases, cartilage defects are
replaced by fibrous cartilage that exhibits significantly
inferior mechanical properties.5-7 The progression of OA
is represented by multiple detrimental events, starting
with the death of chondrocytes, followed by the upregu-
lation of proteolytic enzymes.8,9 Weight loss, low-impact
exercise and the strengthening of muscles are generally
recommended to help slow its progression. A common
practice also includes administration of non-steroidal
anti-inflammatory medicines, as well as injection of
cortisone and hyaluronic acid.10 Surgical treatments
might be an ultimate choice. However, it introduces the
risk of infection and damage to surrounding structures.11,12
Pre-clinical and clinical studies have been conducted
with naturally derived chemicals, synthetic agents, and
biological molecules.13-17 In this study, we focused on
Salubrinal (Tocris Bioscience, Bristol, United Kingdom,
C21H17C13N4OS, 480 Da), a synthetic chemical, as a poten-
tial chondroprotective agent. Salubrinal has been shown
to prevent bone loss by elevating the phosphorylation
level of eukaryotic translation initiation factor 2 alpha
(eIF2α).18 This elevation upregulates activating transcrip-
tion factor 4 (ATF4), which is one of the key transcription
factors in bone formation.19,20 Furthermore, an increase
in eIF2α phosphorylation is reported to inhibit bone
resorption by inactivating the nuclear factor of activated
T-cells, cytoplasmic 1 (NFATc1).20,21 Because of Salubrinal’s
dual beneficial role in protecting and rebuilding bone, an
intriguing issue is its potential effect on cartilage. We have
shown previously that Salubrinal downregulates expres-
sion and activity of matrix metalloproteinase 13 (MMP13)
in C28/I2 chondrocytes.22 However, its efficacy in the
treatment of OA needs to be examined.
Herein, we address a pair of questions using primary
chondrocytes and a mouse model of post-traumatic OA:
does Salubrinal chondroprotect the damaged articular
cartilage? If so, what signalling pathway mediates its
effect? Based on our previous study using C28/I2
chondrocytes, we focused on nuclear factor kappa B
(NFB) signalling and assayed MMP13 activity. We used
Guanabenz (Tocris Bioscience) as a positive control as a
regulator of eIF2α phosphorylation. We also evaluated
the response to TNFα in primary and C28/I2
chondrocytes, and examined the efficacy of Salubrinal in
a mouse model of OA using histology.23,24
Materials and Methods
Cell culture. Human primary chondrocytes (PC136121A1-C,
Asterand Bioscience, Cambridge, Massachusetts) and
human chondrocyte cell line, C28/I2, were cultured in
DMEM/F12 and DMEM mediums, respectively, which
were supplemented with 10% fetal bovine serum and
antibiotics (Life Technologies, Grand Island, New York).
Cells were maintained at 37°C and 5% CO2 in a humidi-
fied incubator. After ten hours of serum-free conditions,
cells were incubated with 10 ng/ml TNFα (R&D Systems,
Minneapolis, Minnesota) in the presence and absence of
5 μM Salubrinal or 5 μM Guanabenz (TOCRIS Bioscience,
Ellisville, Missouri). One μM thapsigargin (Santa Cruz
Biotechnology, Santa Cruz, California) was used as a
positive control (PC) for phosphorylation of eIF2α.
A mouse model of OA and administration of Salubrinal
or Guanabenz. OA was surgically induced in the left
knees of 118 C57/BL6 female mice (approximately nine
weeks old) by transecting the medial collateral ligament
and removing the medial meniscus.23 Animal groups
included age-matched sham control (CN), OA placebo,
and OA treated with Salubrinal (OA + Sal). The sham
surgery consisted of incision and suture. We also
employed additional age-matched sham control and two
OA groups treated with Guanabenz and its solvent
(placebo). A total of three days after the induction of OA,
Salubrinal (1.5 mg/kg) or Guanabenz (2.0 mg/kg) was
administered daily into an intra-articular space, while
their solvents (49.5% PEG 400 and 0.5% Tween 80 in PBS
for Salubrinal; and distilled water including 5% glucose
for Guanabenz) were used in the placebo groups. Mice
were anaesthetised, after which injection was conducted
to the intercondylar fossa from the patellar tendon in a
sagittal plane to avoid potential damage to the load-
bearing cartilage surface.
Western blot analysis. Human primary chondrocytes
(15 minutes after addition of TNFα) and tibia cartilage (three
weeks after the induction of OA) were lysed in a radio-
immunoprecipitation assay buffer.22 We chose a tibia sam-
ple as they were able to be harvested with fewer potential
contaminations with subchondral bone or bone marrow
than femur samples. Isolated proteins were gel-fractionated
and electro-transferred to Immobilon-P membranes
(Millipore, Billerica, Massachusetts). The antibodies used
were phosphorylated NFB p65, NFB p65 (Cell Signaling,
Beverly, Masachusetts) and β-actin (Sigma, St Louis,
Missouri). Images were taken with a luminescent image
analyser (LAS-3000, Fuji Film, Tokyo, Japan), and signal
intensities were quantified with Image J software (National
Institute of Health, Bethesda, Maryland). Data were
presented with reference to control intensities of β-actin.
Safranin O staining. Knee samples were decalcified in
10% ethylenediaminetetraacetic acid (EDTA) for two
weeks, embedded in paraffin and sectioned at 4 μm thick-
ness. After deparaffinisation and rehydration, slides were
stained with Weigert’s iron haematoxyline solution for
five minutes. They were differentiated in 1% acid–alcohol,
and stained with 0.02% fast green solution. They were
then rinsed in 1% acetic acid, stained in 1% Safranin O
solution for 30 minutes and treated with graded ethyl
alcohol and xylene.25
Histological score for symptoms of osteoarthritis. Tissue
sections (approximately 50 sections per mouse) were graded
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using the scoring system described by Glasson et al.24
Because of the specific procedure taken for OA induction,
we focused on the histological evaluation of the medial
side that exhibited more severe symptoms than the lateral
side. Accordingly, the grade was assigned by two
independent scorers blinded to treatment allocation (KH,
AN) as follows: “0” = normal; “0.5” = loss of Safranin O
without structural changes; “1” = small fibrillations
without loss of cartilage; “2” = vertical clefts down to the
layer immediately below the superficial layer and some
loss of surface lamina; and “3” to “6” = vertical clefts/
erosion to the calcified cartilage extending to < 25%,
25% to 50%, 50% to 75%, and > 75% of the articular
surface, respectively.
Determination of thickness of subchondral bone and
synovial score. To evaluate the effects of OA induction on
subchondral bone, its average thickness was determined
using the procedure described previously.26 In brief, the
area of subchondral bone was measured using Image J
software. The average thickness was then determined as a
ratio of subchondral bone area to its weight-bearing
width. We also determined synovial scores for evaluating
inflammation of the synovium using the procedure
described previously.27
MMP13 activity. Proteins were isolated from primary
chondrocytes or tibial cartilage samples (three weeks
after the induction of OA) and lysed in a radioimmuno-
precipitation assay buffer. MMP13 activity was analysed
with a SensoLyte 520 MMP-13 assay kit (AnaSpec,
Fremont, California) according to the manufacturer’s
instruction. In brief, the lysates were incubated with
APMA at 37°C for 40 minutes. The mixtures were then
combined with MMP13 substrate solutions and
incubated at 37°C for 30 minutes. Fluorescence intensity
for MMP13 activity was determined at 485 nm
(excitation) and 528 nm (emission).
Statistical analysis. For in vitro experiments, three or four
independent experiments were conducted and the
Student’s t-test was employed. For the evaluation of
histological scores, thickness of subchondral bone, and
synovial scores, non-parametric statistical analysis
(Kruskal–Wallis test and Mann–Whitney U test) was
conducted. For the interpretation of in vivo protein samples,
one-way analysis of variance followed by Dunnett’s post
hoc test, was conducted. Data were expressed as mean
and standard deviation (SD), and statistical significance
was evaluated at p < 0.05. The single and double asterisks
indicate p < 0.05 and p < 0.01, respectively.
Results
In vitro suppression of TNFα-induced NFB phosphoryla-
tion and MMP13 activity by Salubrinal. In response to
10 ng/ml of TNFα, primary chondrocytes (PC136121A1-C)
elevated the level of phosphorylated NFB (p-NFB) with-
out altering the total level of NFB (Fig. 1a). Their incuba-
tion with TNFα also increased MMP13 activity (Fig. 1b).
However, simultaneous application of 5 μM of Salubrinal
with TNFα significantly reduced the level of p-NFB as
well as MMP13 activity (Figs 1a and 1b). Although both
Salubrinal and Guanabenz elevate the phosphorylation
level of eIF2α, Guanabenz did not alter the level of p-NFB
(Fig. 1c) or MMP13 activity (Fig. 1d).
Reduced cartilage degradation by Salubrinal into the
intra-articular space. In the mouse model of osteoarthri-
tis, the sagittal sections stained with Safranin O indicated
degradation of articular cartilage on the tibial and femo-
ral surfaces in the knee joint (Fig. 2). The intensity of
Safranin O staining decreased in the samples harvested
three and six weeks after the induction of OA. However,
daily administration of Salubrinal at a dose of 1.5 mg/kg
from three days after the induction of OA partially
restored Safranin O staining.
The histological score (0 for normal, and 6 for worst
OA) revealed that Salubrinal significantly reduced OA-
linked tissue degeneration (Fig. 3). In week three samples,
the histological mean scores for the medial femoral
condyle (MFC) were 0.8, SD 0.3 (control; CN), 3.8, SD 1.2
(OA placebo; OA), and 2.5, SD 0.5 (OA Salubrinal; OA +
Sal) (CN vs OA, p < 0.01; and OA vs OA + Sal, p = 0.045),
while the scores for the medial tibial plateau (MTP) were
0.3, SD 0.5 (CN), 2.8, SD 1.0 (OA), and 2.2, SD 0.8 (OA +
Sal) (CN vs OA, p < 0.01; and OA vs OA + Sal, p = 0.530).
In week six samples, the scores for MFC were 0.6, SD 0.2
(CN), 5.1, SD 0.8 (OA), and 4.0, SD 1.9 (OA + Sal) (CN vs
OA, p < 0.01; and OA vs OA + Sal, p = 0.163), while the
scores for MTP were 0.6, SD 0.4 (CN), 5.3, SD 0.7 (OA),
and 3.7, SD 1.8 (OA + Sal) (CN vs OA, p < 0.01; and OA vs
OA + Sal, p = 0.027).
Increased subchondral bone formation and marginal
osteophyte development are part of the joint pathology
in OA. In the mouse model of OA in this study, the thick-
ness of subchondral bone was not altered in week three
samples, but it was significantly increased in MFC and
MTP in week six samples (Fig. 4a). Administration of
Salubrinal did not alter the thickness of MFC and MTP at
either time points. Regarding synovial inflammation,
induction of OA worsened the synovial score in week
three and week six samples (Fig. 4b). Salubrinal reduced
the score in both samples, although statistically signifi-
cant reduction was observed only in week three samples.
In vivo suppression of OA-induced NFB phosphoryla-
tion and MMP13 activity by Salubrinal. Protein samples
harvested from the tibial cartilage, showed upregulation
of p-NFB as well as MMP13 activity compared with the
age-matched sham control (Fig. 5). Consistent with the
in vitro result, daily administration of Salubrinal signifi-
cantly reduced p-NFB (p-NFB/β-actin CN vs OA,
p = 0.001; OA vs OA + Sal, p = 0.023; and p-NFB/NFB
CN vs OA, p = 0.285; OA vs OA + Sal, p = 0.042) as well as
MMP13 activity (CN vs OA, p < 0.001; and OA vs OA + Sal,
p < 0.001). Of note, TNFα in the in vitro assay did not alter
the level of total NFB, however, OA protein samples
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presented an elevated level of NFB. We also evaluated
the levels of p-eIF2α in the mouse cartilage samples as
well as C28/I2 chondrocytes, in which 1 μM thapsigargin
was employed as a positive control (PC) of elevation of
p-eIF2α. In the cartilage samples, the significant
elevation of p-eIF2α was not detected (Fig. 6a). In vitro
chondrocyte samples did not also present statistically
significant elevation of p-eIF2α in response to TNFα
with and without 5 μM Salubrinal (Fig. 6b).
Collectively, the result showed that Salubrinal-driven
suppression of p-NFB was not directly linked to the
regulation of p-eIF2α.
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Fig. 1a
Graphs and staining showing the response of human primary chondrocytes to tumour necrosis factor alpha (TNF) in the presence and absence of Salubrinal (Sal)
or Guanabenz (Gu), with a) activation of nuclear factor kappa B (NFB) by TNF for 15 minutes and partial deactivation by Salubrinal, b) matrix metalloproteinase
(MMP)13 activity induced by TNF and suppressed by 5 μM Salubrinal, c) no detectable effect of Guanabenz on the level of p-NFB and d) no detectable change
of MMP13 activity by Guanabenz shown. CN, vehicle.
Fig. 1b
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Fig. 2a
Images of safranin O staining of the sagittal knee joint section, with a) samples three weeks after induction of osteoarthritis (OA, placebo sample; OA + Sal,
Salubrinal-treated OA sample; CN, sham control sample) and b) samples six weeks after induction of OA shown. The three panels in the top row show an entire
knee section (bar = 200 μm), while the three panels in the bottom row depict their enlarged images (bar = 100 μm). The top section in each panel is the femur,
and the bottom section is the tibia.
Fig. 2b
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No suppressive effects to OA progression with
Guanabenz. In response to Guanabenz, the progres-
sion of OA was not detectably changed in the femur
(MFC) and the tibia (MTP) both in week three and
week six samples (Fig. 7). In week six samples, for
example, the histological score for MFC was 0.8, SD 0.3
(CN), 5.1, SD 0.8 (OA), and 5.2, SD 0.7 (OA + Gu) (CN
vs OA, p < 0.01; and OA vs OA + Gu, p = 0.772), while
the score for MTP was 0.6, SD 0.4 (CN), 4.8, SD 0.7
(OA), and 4.7, SD 0.5 (OA + Gu) (CN vs OA, p < 0.01;
and OA vs OA + Gu, p = 0.758). Compared with the OA
control samples, administration of Guanabenz did not
alter the thickness of subchondral bone of MFC and
MTP at either time points (Fig. 8a). Unlike Salubrinal,
which significantly reduced the synovial score in week
three samples, Guanabenz did not change the
synovial score both in week three and week six
samples (Fig. 8b).
No significant effects on the contralateral knee.
Examination of the contralateral knee, which did not
receive surgery for OA induction or administration of
Salubrinal or Guanabenz, revealed that no significant
effects were detected on thickness of subchondral
bone or histological scores.
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Fig. 3a
Graphs showing histological scores for progression of osteoarthritis (OA), for a) medial femoral condyle (MFC) (left) and medial tibial plateau (MTP) (right)
three-week samples (n = 6) and b) for MFC (left) and MTP (right) six-week samples (n = 5 sham control, CN, 8 OA + placebo, and 7 OA + Salubrinal (Sal)) are
shown; *p < 0.05; **p < 0.01.
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Fig. 4a
Graphs showing the effects of Salubrinal on subchondral bone and synovium, with a) thickness of subchondral bone in the medial femoral condyle (MFC) (left)
and medial tibial plateau (MTP) (right) (three weeks top row, six weeks bottom row) and b) synovial score for three-week (left) and six-week (right) samples.
*p < 0.05; **p < 0.01.
Fig. 4b
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Discussion
This study demonstrates that daily administration of
Salubrinal attenuates the degradation of the tibial and
femoral articular cartilage and the inflammation of
synovium by downregulating NFB signalling. Salubrinal’s
suppressive effects on the proteolytic activity of MMP13,
as well as its elevation of the phosphorylation of
NFB p65 in the mouse model of OA, were consistent
with in vitro data. The OA model in the current study
induced damage in the medial collateral ligament and the
medial meniscus. As post-traumatic OA may cause
injuries in those regions, the results shown in this study
may support the idea that Salubrinal can be applied to
treat OA resulting from traumatic joint injuries.
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Graphs showing suppression of p-nuclear factor kappa B (p-NFB) p65 and activity of matrix metalloproteinase 13 (MMP13) by Salubrinal in a mouse model
of osteoarthritis; (n = 12 CN, sham control, 10 OA placebo, and 11 OA + Salubrinal (Sal)), with a) attenuation of the level of p-NFB p65 by Sal and
b) suppression of activity of MMP13 by Sal shown.
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Graphs and staining showing evaluation of the phosphorylation level of eukaryotic translation initiation factor 2 alpha (eIF2) in cartilage samples and
C28/I2 chondrocytes, with a) levels of p-eIF2 in tibial cartilage samples (three weeks after the induction of osteoarthritis; OA); (n = 12 CN, sham
control, 10 OA placebo, and 11 OA + Salubrinal (Sal)) and b) levels of p-eIF2 in C28/I2 chondrocytes treated with TNF in the presence and absence
of 5 μM Salubrinal for 15, 30, and 360 minutes shown. Thapsigargin at 1 μM was used as a positive control (PC) for p-eIF2.
Fig. 6b
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The progression of symptoms of OA differed between
the tibia and femur, and the efficacy of Salubrinal
depended on time points. In response to Salubrinal,
significant suppression of cartilage degradation was
identified three weeks after the induction of OA in the
femur, while in the tibia it was six weeks. Although the
mean histological score at week three for the Salubrinal-
treated OA group was similar in the femur (2.5, SD 0.5)
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Fig. 7a
Histological images and graphs showing no significant prevention of the progression of osteoarthritis (OA) by Guanabenz (Gu). Safranin O staining of the
sagittal knee joint section and histological scores, with a) samples three weeks after induction of OA; (n = 6 CN, control sham, 9 OA placebo and OA + Gu) and
b) samples six weeks after induction of OA; (n = 5 CN, and 9 OA, and OA + Gu) shown. OA, OA placebo sample; OA + Gu-treated OA sample.
Fig. 7b
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Fig. 8a
Graphs showing the effects of Guanabenz on subchondral bone and synovium, with a) thickness of subchondral bone for three-week (top) and six-week
(bottom) samples in the medial femoral condyle (MFC) (left) and medial tibial plateau (MTP) (right) and b) synovial score for three-week (left) and six-week
(right) samples.*p < 0.05; **p < 0.01.
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and the tibia (2.2, SD 0.8), the mean week three score for
the OA placebo group was 3.8, SD 1.2 (femoral) and 2.8,
SD 1.0 (tibial), indicating that the initial phase was more
severe in the femur than in the tibia. In the week six OA
placebo group, the mean score approached the worst
score of six in the femur (5.1, SD 0.8) and in the tibia
(5.3, SD 0.7). Significant suppression of OA symptoms
was detected only in the tibia samples, although the
actual mean histological score was close between the
femur (4.0, SD 1.9) and the tibia (3.7, SD 1.8).
Although Salubrinal is known to reduce stress to the
endoplasmic reticulum, the mechanism of Salubrinal’s
action in the current study does not appear to be linked to
eIF2α regulation. Guanabenz is another agent that
upregulates phosphorylation of eIF2α. Unlike Salubrinal,
however, Guanabenz does not alter the level of p-NFB or
reduce activity of MMP13. We have previously shown
using C28/I2 chondrocytes that silencing NFB p65
suppressed TNFα-driven upregulation of MMP13.22 In
this study, in vivo and in vitro data support the notion that
Salubrinal’s chondroprotection results from the down-
regulation of p-NFB (Fig. 9). We evaluated MMP13 activ-
ity, as MMP13 degrades not only collagen, but also
aggrecan, and it is the most highly expressed collagenase
in patients with OA.28
Regarding NFB signalling, differential regulation of
total protein levels of NFB was observed in in vitro and
in vivo experiments. Although the level of p-NFB was
elevated in both TNFα-stimulated primary chondro-
cytes and the OA tibial cartilage, the total protein level
of NFB was increased in the OA cartilage but not in
TNFα-stimulated chondrocytes. This difference is
potentially caused by the short incubation time
(15 mins) with TNFα. Alternatively, in addition to TNFα,
inflammatory factors such as IL1β likely contributed to
the elevation of NFB in the OA cartilage.29
Administration of Salubrinal for pre-clinical treatment
of various diseases has been tested for diabetes,18
Alzheimer’s disease30 and osteoporosis.31 We, therefore,
employed a mouse model of OA and showed that injec-
tion of Salubrinal into the intra-articular space delayed
the progression of OA. Multiple strategies for treatment
of OA have been considered, including transplantation of
MSCs, antibodies directed to inflammatory cytokines,
synthetic and natural chemical agents, and mechanical
stimulation.25 Although Salubrinal prevents bone
resorption and the stimulation of subchondral bone
formation is part of the joint pathology in OA, the current
mouse model of OA did not show any increase in
thickness of subchondral bone in response to Salubrinal.
Thus, Salubrinal is potentially able to attenuate the
degradation of articular cartilage and the inflammation of
synovium without causing a pathological thickening of
subchondral bone.
There are several factors that might facilitate further
evaluation of the efficacy of Salubrinal. First, an
extended period of chondroprotection beyond three to
six weeks could be evaluated by selecting proper dosages
and administration frequencies. Second, daily intra-
articular injection may not provide a convenient option in
clinical situations. Sustained delivery of Salubrinal could
be examined using implantable scaffolds or targeted
nanoparticles.32 Third, with the exception of Salubrinal’s
effects on chondroprotection, it is important to
examine the effects on chondroregeneration including
expression of matrix components such as type II
collagen and aggrecan. 
In conclusion, we have demonstrated that Salubrinal
attenuated degradation of articular cartilage by
inhibiting MMP13 activity through NFB signalling.
Further analysis regarding administration frequency
and most effective dosage may warrant a future clinical
trial in patients with OA.
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Additional graphs showing no significant effects
of osteoarthritis induction and administration of
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available with the online version of this article at
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